Insider Selling: AngioDynamics, Inc. (NASDAQ:ANGO) Director Sells $292,792.50 in Stock

AngioDynamics, Inc. (NASDAQ:ANGO) Director Kevin J. Gould sold 13,650 shares of AngioDynamics stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $21.45, for a total value of $292,792.50. Following the transaction, the director now directly owns 61,774 shares of the company’s stock, valued at approximately $1,325,052.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of ANGO stock opened at $21.19 on Friday. The company has a 50-day moving average price of $19.94. AngioDynamics, Inc. has a twelve month low of $18.11 and a twelve month high of $25.48. The firm has a market cap of $801.26 million, a P/E ratio of 25.53 and a beta of 0.69. The company has a quick ratio of 3.75, a current ratio of 4.30 and a debt-to-equity ratio of 0.20.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Wednesday, July 10th. The medical instruments supplier reported $0.25 earnings per share for the quarter, missing the consensus estimate of $0.26 by ($0.01). AngioDynamics had a net margin of 17.06% and a return on equity of 5.58%. The firm had revenue of $96.30 million during the quarter, compared to analyst estimates of $92.34 million. During the same period in the previous year, the firm posted $0.20 EPS. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. On average, sell-side analysts predict that AngioDynamics, Inc. will post 0.27 EPS for the current year.

A number of hedge funds have recently made changes to their positions in ANGO. Nisa Investment Advisors LLC raised its stake in AngioDynamics by 100.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,200 shares of the medical instruments supplier’s stock valued at $43,000 after purchasing an additional 1,100 shares during the last quarter. Advisor Group Inc. increased its stake in shares of AngioDynamics by 21.4% during the 4th quarter. Advisor Group Inc. now owns 3,405 shares of the medical instruments supplier’s stock valued at $68,000 after acquiring an additional 601 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of AngioDynamics by 28.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 5,315 shares of the medical instruments supplier’s stock valued at $107,000 after acquiring an additional 1,181 shares during the last quarter. BNP Paribas Arbitrage SA increased its stake in shares of AngioDynamics by 121.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 8,883 shares of the medical instruments supplier’s stock valued at $203,000 after acquiring an additional 4,880 shares during the last quarter. Finally, Piedmont Investment Advisors Inc. acquired a new position in shares of AngioDynamics during the 1st quarter valued at about $213,000. 98.47% of the stock is owned by hedge funds and other institutional investors.

Several research firms have recently issued reports on ANGO. TheStreet downgraded Upland Software from a “b-” rating to a “c+” rating in a research note on Wednesday, July 10th. BidaskClub raised shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a research note on Friday, July 12th. Zacks Investment Research raised shares of Investar from a “hold” rating to a “buy” rating and set a $27.00 target price for the company in a research note on Tuesday, June 4th. Finally, ValuEngine downgraded shares of Zumiez from a “hold” rating to a “sell” rating in a research note on Tuesday, July 2nd. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $21.50.

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Featured Article: What is a death cross?

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.